Amyloidosis Incidence in High-Risk Cardiac Device Patients

Launched by MIDWEST HEART & VASCULAR SPECIALISTS · Dec 16, 2023

Keywords

ClinConnect Summary

This clinical trial is looking into how to better diagnose cardiac amyloidosis, a condition where abnormal proteins build up in the heart and can cause serious health issues. The study will focus on high-risk patients who are scheduled to have standard heart devices implanted, such as pacemakers. Researchers will collect and analyze a small sample of fat tissue from the chest, which is usually thrown away, to see if it can help identify amyloidosis. They hope that by combining this information with other health data, they can create a better screening method for the condition.

To participate in this study, you need to be at least 40 years old, able to give consent, and have certain signs that suggest you might have cardiac amyloidosis. The study will enroll about 100 patients and will run from December 2023 to December 2024. If you qualify and decide to join, you can expect to help improve the way this serious condition is diagnosed, potentially leading to better treatment options in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients who are 40 years of age or older
• • Patients who are able and willing to provide informed consent
• • Patients who are scheduled for CIED implantation within the study period and with clinical lab and imaging features suggestive of cardiac amyloidosis
• Exclusion Criteria:
• • Individuals below the age of 40.
• • Persons who are unable to consent or who do not consent to participate.
• • Patients who have already been diagnosed with cardiac amyloidosis prior to the study